Jared Baeten1, Connie Celum. 1. Department of Global Health, University of Washington, Seattle, Washington, USA. jbaeten@uw.edu
Abstract
PURPOSE OF REVIEW: Preexposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use oral antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. RECENT FINDINGS: During the past 2 years, proof-of-concept that PrEP protects against sexual HIV acquisition has been demonstrated in three clinical trials, conducted among MSM and heterosexual men and women. These trials used daily oral tenofovir disoproxil fumarate, alone or coformulated with emtricitabine. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Two additional clinical trials, both among heterosexual women, did not demonstrate HIV protection with PrEP, with low adherence to daily use of PrEP the leading hypothesis for lack of efficacy; adherence and biologic mechanisms for lack of efficacy in these trial populations are being evaluated. SUMMARY: Oral chemoprophylaxis, using tenofovir and combination emtricitabine-tenofovir, is effective for prevention of sexual HIV transmission. Next steps in the field include rigorous evaluation of uptake and adherence to PrEP in implementation settings.
PURPOSE OF REVIEW: Preexposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use oral antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. RECENT FINDINGS: During the past 2 years, proof-of-concept that PrEP protects against sexual HIV acquisition has been demonstrated in three clinical trials, conducted among MSM and heterosexual men and women. These trials used daily oral tenofovir disoproxil fumarate, alone or coformulated with emtricitabine. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Two additional clinical trials, both among heterosexual women, did not demonstrate HIV protection with PrEP, with low adherence to daily use of PrEP the leading hypothesis for lack of efficacy; adherence and biologic mechanisms for lack of efficacy in these trial populations are being evaluated. SUMMARY: Oral chemoprophylaxis, using tenofovir and combination emtricitabine-tenofovir, is effective for prevention of sexual HIV transmission. Next steps in the field include rigorous evaluation of uptake and adherence to PrEP in implementation settings.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: J Gerardo García-Lerma; Mian-er Cong; James Mitchell; Ae S Youngpairoj; Qi Zheng; Silvina Masciotra; Amy Martin; Zsuzsanna Kuklenyik; Angela Holder; Jonathan Lipscomb; Chou-Pong Pau; John R Barr; Debra L Hanson; Ron Otten; Lynn Paxton; Thomas M Folks; Walid Heneine Journal: Sci Transl Med Date: 2010-01-13 Impact factor: 17.956
Authors: Charles S Chasela; Michael G Hudgens; Denise J Jamieson; Dumbani Kayira; Mina C Hosseinipour; Athena P Kourtis; Francis Martinson; Gerald Tegha; Rodney J Knight; Yusuf I Ahmed; Deborah D Kamwendo; Irving F Hoffman; Sascha R Ellington; Zebrone Kacheche; Alice Soko; Jeffrey B Wiener; Susan A Fiscus; Peter Kazembe; Innocent A Mofolo; Maggie Chigwenembe; Dorothy S Sichali; Charles M van der Horst Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black Journal: Science Date: 1995-11-17 Impact factor: 47.728
Authors: Nicola Low; Matthew F Chersich; Kurt Schmidlin; Matthias Egger; Suzanna C Francis; Janneke H H M van de Wijgert; Richard J Hayes; Jared M Baeten; Joelle Brown; Sinead Delany-Moretlwe; Rupert Kaul; Nuala McGrath; Charles Morrison; Landon Myer; Marleen Temmerman; Ariane van der Straten; Deborah Watson-Jones; Marcel Zwahlen; Adriane Martin Hilber Journal: PLoS Med Date: 2011-02-15 Impact factor: 11.069
Authors: J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine Journal: PLoS Med Date: 2008-02 Impact factor: 11.069
Authors: Poloko M Kebaabetswe; Michael J Stirratt; Eleanor McLellan-Lemal; Faith L Henderson; Simone C Gray; Charles E Rose; Tiffany Williams; Lynn A Paxton Journal: AIDS Behav Date: 2015-05
Authors: Sarit A Golub; Kristi E Gamarel; H Jonathon Rendina; Anthony Surace; Corina L Lelutiu-Weinberger Journal: AIDS Patient Care STDS Date: 2013-04 Impact factor: 5.078
Authors: Robyn M Engel; Monica Morris; Tara Henning; Jana M Ritter; Tara L Jones; Sharon Dietz; Jessica Ayers; Sundaram A Vishwanathan; Leecresia Jenkins; Sherif Zaki; Dirk Wildemeersch; David Garber; Nathaniel Powell; R Michael Hendry; Janet McNicholl; Ellen N Kersh Journal: J Med Primatol Date: 2013-12-27 Impact factor: 0.667
Authors: Tareerat Chemnasiri; Anchalee Varangrat; K Rivet Amico; Anupong Chitwarakorn; Bonnie J Dye; Robert M Grant; Timothy H Holtz Journal: AIDS Care Date: 2019-06-03